Subcutaneous amivantamab plus chemotherapy offers an equally effective treatment for EGFR exon 20 insertion non–small cell lung cancer (NSCLC), mirroring PAPILLON results of the intravenous formulation, explained Sun Lim Min, MD, PhD.
Sun Lim Min, MD, PhD
Advertisement
Sun Min Lim, MD, PhD, works in the Division of Medical Oncology in the Department of Internal Medicine at Yonsei University College of Medicine in Seoul, South Korea.
Articles by Sun Lim Min, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
2
Oz White House Briefing Touts Drug Savings and Fraud Cleanup, but Data Tell a Nuanced Story
3
Plastic in Personal Care Products Tied to Skin Disease and Environmental Pollution, Review Finds
4
Three Years on Baricitinib Preserved Hair Regrowth in Severe Alopecia Areata
5